Quanterix Appoints William Geist as Chief Operating Officer
Geist brings operational experience to
“Quanterix is experiencing strong momentum across numerous digital biomarker platforms supporting drug development and non-invasive, early disease diagnostics research ,” said
Geist brings over 25 years of experience to
In his role, Geist will build on Quanterix’ track record of strong execution as the Company expands globally and continues to disrupt pharmaceutical development and diagnostics research. Will’s focus will be on execution and continued growth of our ultrasensitive Simoa® technology, including our groundbreaking neurology franchise, as well as opportunities in COVID, Infectious Disease, Immunology and Oncology.
“I am very excited to join
For more information on
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the